“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
A trial looking at doxorubicin with either docetaxel or cyclophosphamide for early, locally advanced or inflammatory breast cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was comparing different combinations of chemotherapy before surgery for breast cancer.
Doctors often give chemotherapy after surgery for early stage breast cancer because it reduces the risk of the cancer coming back. If the tumour in the breast is large, you may have chemotherapy to reduce the size of the tumour before surgery (
The aim of this trial was to see which combination worked best as neoadjuvant treatment for women who had a tumour that was 3cm or more in size, or who had locally advanced or inflammatory breast cancer.
Summary of results
The trial team found that both combinations worked about as well as each other.
The trial recruited 363 women. They had up to 6 cycles of treatment and then had surgery. Half the women had doxorubicin and docetaxel, the other half had doxorubicin and cyclophosphamide.
With the combination of doxorubicin and cyclophosphamide, the cancer responded in 61 out of every 100 women treated (61%). In 17 out of every 100 women (17%) who had this combination, all signs of cancer had disappeared when their breast was examined.
With doxorubicin and docetaxel, the cancer responded in 70 out of every 100 women treated (70%). And with this combination, breast examination showed that all signs of cancer had disappeared in 20 out of every 100 women (20%).
After nearly 3 years of follow up, cancer had come back in 55 of the women who had doxorubicin and cyclophosphamide. It had come back in 45 of the women who had doxorubicin and docetaxel.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor J Evans
The Anglo-Celtic Cooperative Oncology Group